First human CRISPR/Cas9 experiment approved

A US advisory panel has reportedly approved the use of the CRISPR/Cas9 gene-editing technology on humans for the first time, as part of a study designed to target three types of cancer.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

1 April 2026 After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.

Americas

CRISPR priority feud ends at USPTO as board reaches decision

30 March 2026 A long-running patent clash over gene editing returns to a fundamental question, as a US court takes another look at the evidence.

Americas

Masimo convinces judge that Apple took secrets—but it’s not enough

19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.

More features

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

CRISPR priority feud ends at USPTO as board reaches decision

Novartis bets $2bn on biologics as Xolair patents fade

WIPR debuts Global In-House Elite 2026

mRNA litigation: Who’s winning, who’s filing, and what’s next

First human CRISPR/Cas9 experiment approved

More on this story

Editor's picks

Editor's picks

More features